Population modeling of bosutinib exposure‐response in patients with newly diagnosed chronic phase chronic myeloid leukemia

BACKGROUND: The BELA and BFORE trials compared bosutinib starting doses of 500 mg once daily (QD) and 400 mg QD, respectively, with imatinib in adults with newly diagnosed chronic phase chronic myeloid leukemia (CP‐CML). The B1871048 trial evaluated bosutinib 400 mg QD in Japanese patients with newl...

Descripción completa

Detalles Bibliográficos
Autores principales: Garrett, May, Knight, Beverly, Cortes, Jorge E., Deininger, Michael W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524044/
https://www.ncbi.nlm.nih.gov/pubmed/37553873
http://dx.doi.org/10.1002/cam4.6439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524044/
https://www.ncbi.nlm.nih.gov/pubmed/37553873
http://dx.doi.org/10.1002/cam4.6439

Ejemplares similares